Patients who have circumstances that will not permit completion of this study or the required follow-up
Willingness to return to enrolling institution for follow up
Willingness to return to enrolling institution for follow-up during the active monitoring phase (that is, the active treatment and observation portion) of the study); patients who have been formally transferred to another active and approved site participating in this study would not need to return to the enrolling institution for this purpose
Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance
Patients whose circumstances do not permit completion of the study or the required follow-up
Willing to return to Alliance enrolling institution for follow-up
Willing to return to enrolling medical site for all study assessments
Willing to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study; patients are encouraged to return to the enrolling institution; however, patients may receive radiation therapy at a different institution other than the enrolling institution
Willing to return to an Alliance enrolling institution for follow-up
Participants with circumstances that will not permit completion of the study or required follow-up; for instance, if travel to and from treatment site is an issue
Patients with circumstances that will not permit completion of the study or the required follow-up
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
Patients must be deemed able to comply with the treatment plan and follow-up schedule
Subjects with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance
Clinician is comfortable that cancer has adequately been ruled out and is willing to follow the participant for up to 5 years without treatment of the HSIL
Patients unable to follow a low iodine diet or requiring medication with high content in iodide (amiodarone)
Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up
Willingness to return to the enrolling institution for follow-up
Patient must be accessible for follow-up
Active psychosocial condition that would hinder study compliance and follow-up
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
NON-PROGRESSED DIPG (STRATUM 2): Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to drug administration plan, other study procedures, and study restrictions
Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
Patients must have the psychological ability and general health that permits completion of the study requirements and required follow-up
Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up.
Patients who in the opinion of the investigator are unwilling or unable to return for required follow-up visits or obtain follow-up studies required to assess toxicity to therapy or to adhere to device usage plan, other study procedures, and study restrictions
Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up
Willing and able to comply with follow-up schedule
Lack of ability of a patient for immunological and clinical follow-up assessment
Evidence of current drug or alcohol abuse or psychiatric impairment, which in the investigators opinion will prevent completion of protocol therapy or follow-up
